Photocure ASA

OSL:PHO ISIN:NO0010000045

 
 

News

Metvixia(TM) And Aktilite® CL128 Approved By FDA

🕔6/27/2008 4:03:00 PM 9547

Photocure ASA Oslo, Norway, 27 June 2008: Photocure ASA announces today that Metvixia(TM) in combination with Aktilite® CL128, the LED based narrow band (630 nm) red light technology device has been approved by US Food and Drug Administration (FDA) for the treatment of actinic keratosis (AK), a pre-cancerous skin lesion.

Read Full Article

Photocure Ex. PCI Biotech Holding Today

🕔6/17/2008 4:39:00 PM 946

Photocure ASA Oslo, Norway, 16 June 2008

Read Full Article

Demerger PCI Biotech

🕔6/16/2008 4:31:00 PM 797

Photocure ASA Oslo, Norway, 16 June 2008

Read Full Article

PCI Biotech Raises NOK 60 Million In Offering

🕔6/10/2008 5:03:01 PM 1172

Photocure ASA Oslo, 10 June 2008 - PCI Biotech Holding ASA, the Norwegian drug delivery company with a focus on cancer therapeutics, today announced the successful closing of its initial public offering in connection with the listing of the PCI Biotech Holding ASA shares on Oslo Axess (the Share Issue). The offering price was NOK 20 per share. Gross proceeds amounted to NOK 60 million (Approximately USD 11.9 million). PCI Biotech Holding ASA shares are expected to begin trading on the Oslo Axess (ticker: PCIB) on Wednesday 18 June 2008.

Read Full Article

Last Day Including Priority

🕔5/28/2008 5:06:43 PM 735

Photocure ASA Oslo, Norway, 28 May 2008.

Read Full Article
###

3,392 COMPANY PROFILE VIEWS

  • This Page Viewed: (Last 7 Days: 13) (Last 30 Days: 36) (Since Published: 3392) 

Company Data